Redhill Biopharma Ltd. RDHL
0.50
(0.02)
(3.85%)
as of 25 Sep
- Market cap
- $3.2M
- P/E
- 0.0×
Follow RDHL
| Jun '25 | Jun '24 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 19.31 | 26.36 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (33.20) | (174.52) | |
P/B ratio |
— | — | 170.01 | 619.94 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 18.86 | 25.90 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (17.28) | (37.97) | |
EV/FCF |
— | — | (6.63) | (14.24) | |
Quick Ratio |
0.38 | 0.42 | 0.68 | 0.73 | |
Current Ratio |
0.56 | 0.74 | 0.96 | 0.96 | |
Net Debt/EBITDA |
0.00 | 0.00 | 1.95 | 2.29 | |
Debt/Assets |
0.00% | 0.00% | 6.52% | 11.89% | |
Debt/Equity |
0.00 | 0.00 | 0.66 | 3.49 | |
Asset Turnover |
0.00 | 0.00 | 0.30 | 0.42 | |
Operating CF/Net income |
0.00 | 0.00 | (23.62) | (0.14) | |
Capex/Depreciation |
(0.02) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | 69.44% | 30.12% | |
Selling, General and Administrative Expense of Revenue |
— | — | 386.15% | 303.06% | |
Intangible Assets out of Total Assets |
0.30 | 0.25 | 0.16 | 0.10 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 47.81% | 4.04% | |
Graham Net Nets |
— | — | (0.01) | (0.01) | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (2,035.56%) | (793.01%) | |
Free Cash Flow Yield |
— | — | (14.73%) | (6.90%) | |
Revenue per Share |
— | — | 0.09 | 0.29 | |
Operating CF per Share |
0.00 | 0.00 | (0.90) | (0.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.90) | (0.59) | |
Cash per Share |
0.00 | 0.00 | 0.82 | 2.36 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.18 | 0.16 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.18 | 0.16 | |
Free Cash Flow |
(5.02) | (6.19) | (17.78) | (7.12) | |
Working Capital |
(9.73) | (5.53) | (1.14) | (1.92) | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | — | |
Net Current Asset Value |
(10.23) | (6.26) | (4.52) | (10.31) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
— | — | 42.37% | 1,395.98% | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
19.94 | 18.49 | 18.33 | 16.39 | |
Average Payables |
2.53 | 3.35 | 3.74 | 5.04 | |
Average Inventory |
7.09 | 8.19 | 8.33 | 10.07 | |
Average Assets |
88.62 | 89.61 | 101.50 | 112.94 | |
Average Common Equity |
(26.41) | (22.98) | (4.23) | (1.62) |
Columns are period end dates